RxDoctor Payments Data

Travis Dobbs

Family · Toccoa, GANPI 1215461892

Payments from drug & device makers

$5,606in general payments, 2019–2025

Across 351 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Boehringer Ingelheim$498
  • Pfizer$436
  • Bayer$434
  • Novo Nordisk$337
  • AstraZeneca$308
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$5,606100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,606 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$89,097
Medicare patients
172
Services billed
2,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin94$91,765
EliquisApixaban62$38,938
MounjaroTirzepatide31$36,176
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$34,347
OzempicSemaglutide27$26,888
FarxigaDapagliflozin Propanediol32$19,092
TrulicityDulaglutide15$16,694
MyrbetriqMirabegron20$13,427
XareltoRivaroxaban17$12,313
BrilintaTicagrelor27$11,777
EntrestoSacubitril/Valsartan12$11,573
Tresiba Flextouch U-200Insulin Degludec22$10,311
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$9,451
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$8,779
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl59$8,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$498$101,216106 claims
Lilly USA, LLCMounjaro, Trulicity$196$52,87046 claims
PfizerEliquis$436$38,93862 claims
AstraZenecaFarxiga, Brilinta$308$30,86959 claims
Novo NordiskOzempic$337$26,88827 claims
Astellas Pharma US IncMyrbetriq$20$13,42720 claims
Johnson & JohnsonXarelto$16$12,31317 claims
NovartisEntresto$149$11,57312 claims
Indivior Inc.Suboxone$206$3,17912 claims
AbbVieSynthroid$1,125$1,22917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Toccoa

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →